Fortune China released the latest Fortune 500 simultaneously worldwide on the night of July 20, 2016, Beijing Time. More Chinese companies have climbed onto the famed list this year, totaled 110 (including 7 Taiwanese enterprises), among which China National Pharmaceutical Group Corporation, known simply as Sinopharm, ranks 205th and as the only pharmaceutical company from China in the list Sinopharm Group ranks 8th among medical and pharmaceutical companies.
As the largest pharmaceutical and healthcare group under the State-owned Assets Supervision and Administration Commission of the
State Council (SASAC) in China, ranks highest in Comprehensive National Power (CNP) and spans the entire industry chain.
Its core business covers the distribution, retail, research, development and manufacture of prevention, treatment, diagnosis, care and other health-related products. SINOPHARM has 10 whollyowned and controlled subsidiaries and 6 listed companies - SINOPHARM Group Co., Ltd., China National Medicines Co., Ltd. (CNCM), Shenzhen Accord Pharmaceutical Co., Ltd. (Accord), Beijing Tiantan Biological Products Co., Ltd. (TiantanBio), Shyndec Pharmaceutical Co., Ltd. (Shyndec) and China Traditional Chinese Medicine Co., Ltd.
From 2005 to 2016, SINOPHARM's operating revenue, total profits and assets have seen annual average growth rates of 26.89%, 35.28% and 31.16%, respectively. In 2015, SINOPHARM's total operating revenue exceeded RMB270 billion, earning it the distinction as the only Chinese pharmaceutical enterprise to rank among the world's top 500 companies.